Patients with severe burns who have higher levels of vitamin D recover more successfully than those with lower levels, according to a study presented at the Society for Endocrinology annual conference in Harrogate. This study is the first to investigate the role of vitamin D in recovery from burn injury and suggests that vitamin...
Category: <span>Pharmaceutical Updates</span>
Post
New findings on tolvaptan as autosomal dominant polycystic kidney disease treatment
A phase 3 trial studying the effects of tolvaptan has found that the drug slowed the rate of decline in kidney function in patients with the most common form of polycystic kidney disease, a condition with no cure. The results are published today in the New England Journal of Medicine. Autosomal dominant polycystic kidney disease is...
Post
Chemists have created compounds that can treat glaucoma
Glaucoma is a serious disease associated with increased intraocular pressure which often leads to blindness. One of the ways to treat glaucoma is to reduce aqueous humour secretion in the ciliary body of the eye by suppressing (inhibiting) activity of special enzymes – carbonic anhydrases. Russian scientists from RUDN University have designed new compounds that...
Post
New cancer drug shows promise in helping patients with blood cancer
An immunology discovery from the laboratories at the University of Southampton has now been shown to improve the outcomes of a common type of blood cancer in patients. Follicular lymphoma is a type of non-Hodgkin lymphoma and develops when the body makes abnormal white blood cells that fight infection, called B-lymphocytes. It can be slow-growing...
Post
Miracle cure costs less than a budget airline flight
The revolution in generic drugs means that a 12-week course of drugs to cure hepatitis C can be manufactured for just US$50 – as low as the cost of a plane ticket on many low-cost airlines. Furthermore, new data shows that these generic copies are just as effective as the branded medicines. Yet restrictions and...
Post
Drug ‘melts away’ fat inside arteries
A new drug being trialled for treating breast cancer and diabetes has been shown to ‘melt away’ the fat inside arteries that can cause heart attacks and strokes. Researchers from the University of Aberdeen, using pre-clinical mouse models, showed that just a single dose of the drug (Trodusquemine) completely reversed the effects of a disease...
Post
Onalespib could be an effective treatment for glioblastoma, preclinical studies show
The targeted therapy onalespib has shown effectiveness in preclinical studies of glioblastoma by researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James). Onalespib is designed to inhibit a molecule called HSP90. The molecule helps newly made protein molecules fold into...
Post
Getting Drugs Past the Blood-Brain Barrier
To treat neurological disease, researchers develop techniques to bypass or trick the guardian of the central nervous system. ronto, a dozen people huddled in a small room peering at a computer screen. They were watching brain scans of a woman named Bonny Hall, who lay inside an MRI machine just a few feet away. Earlier...
Post
Cheaper drug could release more than GBP 13.5 million a year within the next five years for other services
Doctors in the north east of England face legal action from two of the world’s largest pharmaceutical companies for offering patients with a serious eye condition the choice of a safe, effective but much cheaper drug, reports The BMJ today. Prescribing the cheaper drug could save the region’s NHS up to £13.5m a year within the next...
Post
In the lab and in the clinic, alisertib with TAK-228 excels against solid tumors
University of Colorado Cancer Center investigator, Jennifer Diamond, MD, and colleagues report promising phase I results of alisertib with TAK-228 against solid tumors including triple-negative breast cancer. Two University of Colorado Cancer Center studies were presented this weekend at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting in Philadelphia, PA showing that using the...